12/1
01:35 am
spry
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]
Low
Report
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]
11/26
08:28 am
spry
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
08:00 am
spry
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Low
Report
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
11/22
07:57 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/16
10:26 pm
spry
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks [Yahoo! Finance]
High
Report
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks [Yahoo! Finance]
11/10
04:41 pm
spry
ARS Pharma SPRY Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
ARS Pharma SPRY Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/10
02:04 pm
spry
ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating [Seeking Alpha]
Medium
Report
ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating [Seeking Alpha]
11/10
06:11 am
spry
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) [Yahoo! Finance]
11/10
06:08 am
spry
ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M [Seeking Alpha]
Low
Report
ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M [Seeking Alpha]
11/10
06:00 am
spry
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
Low
Report
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
11/4
09:04 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) is now covered by analysts at Roth Capital. They set a "buy" rating and a $30.00 price target on the stock.
Low
Report
ARS Pharmaceuticals (NASDAQ:SPRY) is now covered by analysts at Roth Capital. They set a "buy" rating and a $30.00 price target on the stock.
11/4
08:00 am
spry
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
Low
Report
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
11/3
02:23 pm
spry
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Low
Report
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
11/3
08:00 am
spry
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
Medium
Report
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
11/3
07:45 am
spry
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Medium
Report
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
10/24
05:33 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
10/8
08:36 am
spry
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) [Yahoo! Finance]
Medium
Report
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) [Yahoo! Finance]
10/8
08:00 am
spry
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
Medium
Report
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
10/4
10:21 am
spry
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? [Yahoo! Finance]
10/3
03:30 pm
spry
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
07:44 am
spry
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies [Yahoo! Finance]
Low
Report
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies [Yahoo! Finance]
9/29
04:24 pm
spry
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy® [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy® [Yahoo! Finance]
9/29
04:05 pm
spry
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Medium
Report
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
9/26
12:03 pm
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was given a new $32.00 price target on by analysts at Raymond James Financial, Inc..
Low
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was given a new $32.00 price target on by analysts at Raymond James Financial, Inc..
9/19
08:37 am
spry
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]
Medium
Report
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]